IGF-1R and FGFR are continuously activated in sorafenib-resistant HCC, and these sorafenib-resistant tumor cells exhibit greater tumor-initiating capacity in vivo (Tovar et al., 2017). The gene discussed is IGF1R; the disease is neoplasm.